Posted On: 04/23/2015 9:23:50 PM
Post# of 9144
see posts 1474 and 1493
despite a financial crunch while transitioning to a revenue model their balance sheet is much better than many pennies
most co's negotiate this transition via huge convertible debt or other poisonous discounted dilution-which NNLX has chosen not to do-waiting for govt grant applied for 2 months ago or jv or new sales based on recent patents?
unless sales pick up they may have to use 1 of the above funding sources- the chicken and the egg race-and more info and higher otc class to attract the type of investors who can make a large difference and reduce the downward pps pressure that comes w no info class
it is hard for small players to break thru established big pharma type etc relationships to get market share- they have to find a way to do so-
last financials showed 4x increase in revenue yoy-they need to repeat that again unless they want to dilute /debt like most co's do
despite a financial crunch while transitioning to a revenue model their balance sheet is much better than many pennies
most co's negotiate this transition via huge convertible debt or other poisonous discounted dilution-which NNLX has chosen not to do-waiting for govt grant applied for 2 months ago or jv or new sales based on recent patents?
unless sales pick up they may have to use 1 of the above funding sources- the chicken and the egg race-and more info and higher otc class to attract the type of investors who can make a large difference and reduce the downward pps pressure that comes w no info class
it is hard for small players to break thru established big pharma type etc relationships to get market share- they have to find a way to do so-
last financials showed 4x increase in revenue yoy-they need to repeat that again unless they want to dilute /debt like most co's do
(0)
(0)
